<DOC>
	<DOCNO>NCT01236482</DOCNO>
	<brief_summary>In study investigator hypothesize infused combination oxytocin ergometrine exhibit few cardiac neurological side effect equipotent infusion oxytocin alone . In order perform study investigator perform follow step : 1 . The investigator validate quantitative measure uterine tone primary endpoint . 2 . The investigator use endpoint measure order determine equipotential dos different tocotonic drug regimen , base ED50 . 3 . Using equipontial ratio base ED50 , investigator compare hemodynamic side effect tocotonic drug regime . Plasma level oxytocin measure .</brief_summary>
	<brief_title>Oxytocin Cesarean Delivery</brief_title>
	<detailed_description>Obstetric hemorrhage associate severe maternal morbidity×© maternal death . The use tocotonic drug follow delivery routine practice part active management third stage labor , increase uterine tone reduce blood loss . However , use drug without side effect complication . Oxytocin cause profound vasodilatation , hypotension increase cardiac output associate chest pain , reduce arterial oxygen saturation ST segment change ECG . Ergometrine , hand , cause systemic vasoconstriction hypertension , reduce cardiac output . As oxytocin ergometrine associate oppose hemodynamic sequela , rationale justify co-administration drug attempt cancel side effect . No clinical study attempt titrate dose tocotonic drug quantify measure uterine tone . As consequence , comparison hemodynamic side effect oxytocin tocotonic agent ( particularly ergometrine ) base knowledge equipotential dos , make rational comparison side effect impossible . In study hypothesize infused combination oxytocin ergometrine exhibit few cardiac neurological side effect equipotent infusion oxytocin alone . In order perform study perform follow step : 1 ) We validate quantitative measure uterine tone primary endpoint . 2 ) We use endpoint measure order determine equipotential dos different tocotonic drug regimen , base ED50 . 3 ) Using equipontial ratio base ED50 , compare hemodynamic side effect tocotonic drug regime . Plasma level oxytocin measure enable pharmacokinetic-pharmacodynamic assessment make .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<mesh_term>Ergonovine</mesh_term>
	<criteria>80 healthy woman present elective repeat cesarean delivery regional anesthesia . All woman ASA class 12 , age 18 45 , body weight 60100 kg . Obstetric risk factor : Preeclampsia , abnormalities placentation ( eg placenta accrete , placenta previa ) , amnionitis , multiple gestation , preterm delivery ( &lt; 37 complete week ) , three previous cesarean delivery , previous history antepartum postpartum hemorrhage . Maternal medical risk factor : Chronic hypertension , cardiac disease , intracranial pathology , know allergy oxytocin ergometrine , autoimmune disorder , SLE , coagulation defect anticoagulation therapy , amnionitis . Women ask cord blood donation include study due long elapsed time delivery commencement oxytocin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Postpartum hemorrhage</keyword>
	<keyword>Uterine tone</keyword>
	<keyword>Oxytocin</keyword>
	<keyword>Ergometrine</keyword>
	<keyword>Pharmacokinetic-pharmacodynamic analysis</keyword>
</DOC>